FRANKFURT AM MAIN, GERMANY | January 26, 2026 — Merz Therapeutics has completed and submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for a new pediatric indication of XEOMIN® (incobotulinumtoxinA) for the treatment of upper- and lower-limb spasticity in children and adolescents aged 2–17 years across the European Union (EU) and European Economic Area (EEA). The submission represents a major milestone in expanding the clinical use of a well-established botulinum neurotoxin therapy into younger patient populations with significant unmet neurological needs.
Science Significance
The scientific importance of this submission lies in the application of a purified botulinum neurotoxin formulation to pediatric neurology, an area requiring precise dosing, robust safety data, and strong mechanistic understanding. Spasticity, commonly associated with cerebral palsy (CP) and other neurological disorders, results from abnormal muscle tone driven by dysregulated neuromuscular signaling. IncobotulinumtoxinA works by inhibiting acetylcholine release at the neuromuscular junction, thereby reducing excessive muscle contraction. The EMA submission is supported by a comprehensive clinical dossier, including data from the Phase 3 ELLIE trial, a randomized, placebo-controlled, double-blind, multicenter study that demonstrated statistically significant improvements in lower-limb spasticity alongside a favorable safety and tolerability profile in pediatric patients.
Regulatory Significance
From a regulatory standpoint, the application represents a major lifecycle management milestone for an established medicinal product. Pediatric indications require heightened regulatory scrutiny, including stringent evaluation of long-term safety, developmental impact, and ethical trial design. The submission includes updated clinical evidence from multiple pediatric investigations, addressing both lower- and upper-limb spasticity and reflecting EMA expectations for indication expansion in vulnerable populations. For cGxP professionals, the filing highlights the importance of GCP-compliant pediatric trial execution, pharmacovigilance planning, and risk–benefit assessment when extending adult therapies into pediatric use.
Business Significance
Advertisement
Strategically, the EMA submission strengthens Merz Therapeutics’ position as a neurology-focused specialty pharma company with a long-term commitment to movement disorders. Expanding XEOMIN® into pediatric spasticity broadens the product’s addressable market while reinforcing its clinical differentiation based on purity and established clinical performance. Approval would allow Merz to leverage existing manufacturing, quality systems, and medical affairs infrastructure across Europe, supporting sustainable growth without the risks associated with launching an entirely new molecular entity. The move also enhances Merz’s reputation as a company willing to invest in complex, regulation-intensive pediatric development programs.
Patients’ Significance
For patients and families, the potential impact is substantial. Children with spasticity often experience limited mobility, pain, and reduced independence, with severe cases affecting speech, swallowing, and fine motor skills. Access to an approved, evidence-based botulinum toxin therapy could significantly improve functional outcomes and quality of life for pediatric patients across Europe. Importantly, a formal pediatric indication ensures that treatment decisions are supported by robust clinical evidence, standardized dosing guidance, and regulatory oversight, reducing reliance on off-label use in this vulnerable population.
Policy Significance
At a policy level, the submission aligns with European public health priorities focused on improving pediatric access to safe, effective neurological therapies. Regulators increasingly encourage evidence-driven expansion of indications for established medicines, particularly when addressing conditions with limited treatment options. Advancing pediatric-specific approvals supports harmonized standards of care across EU member states and reinforces policies promoting ethical pediatric research, long-term safety monitoring, and equitable access to specialized treatments.
The submission of a new pediatric spasticity indication for XEOMIN® to the EMA underscores Merz Therapeutics’ commitment to science-driven, compliance-focused innovation in neurology. Backed by Phase 3 clinical evidence and a comprehensive regulatory dossier, the application exemplifies how established therapies can be responsibly expanded to address unmet needs in younger populations. For the cGxP.wire audience, this development highlights the critical interplay between clinical science, regulatory rigor, and patient-centered strategy in advancing pediatric pharmaceutical care.
Source: Merz Therapeutics press release
